GH Research (GHRS) Non-Current Deferred Tax Liability (2024 - 2025)
GH Research's (GHRS) quarterly Non-Current Deferred Tax Liability came in at $200000.0 in Q4 2025, down 81.82% year-on-year from $1.1 million in Q4 2024, and down 81.82% quarter-over-quarter from $1.1 million in Q4 2024.
GH Research (GHRS) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
GH Research's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $200000.0 for Q4 2025.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 81.82% year-over-year to $200000.0 in Q4 2025; TTM through Dec 2025 was $200000.0, a 81.82% decrease from a year earlier, with the FY2025 full-year figure at $200000.0, down 81.82% from the prior year.
- Non-Current Deferred Tax Liability fell to $200000.0 in Q4 2025 per GHRS's latest filing, from $1.1 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.1 million in Q4 2024 and bottomed at $200000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | GH Research | 1.69 Bn | 1.69 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |